InsiderTrades

Form 4 for BMRN BIOMARIN PHARMACEUTICAL INC

Accepted 2023-03-14 00:00:00 ET · period of report 2023-03-10 · accession 0001567619-23-005059 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2023-03-14 2023-03-10+ BMRN BIENAIME JEAN JACQUES CEO, Dir M - OptEx $67.81 +23.0K 502.9K +5% +$1.56M
DM 2023-03-14 2023-03-10+ BMRN BIENAIME JEAN JACQUES CEO, Dir S - Sale+OE $91.64 -23.0K 487.9K -5% -$2.11M
DM 2023-03-14 2023-03-10+ BMRN BIENAIME JEAN JACQUES CEO, Dir M - OptEx $0.00 -23.0K 149.1K -13% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2023-03-13 M A 8,000 $67.81 495,856 D — — (F2) Trade made pursuant to a 10b5-1 plan executed on November 17, 2022.
2 Common Common Stock 2023-03-13 S D 8,000 $90.45 487,856 D — — (F2) Trade made pursuant to a 10b5-1 plan executed on November 17, 2022.
3 Common Common Stock 2023-03-10 S D 15,000 $92.28 487,856 D — — (F1) Trade made pursuant to a 10b5-1 plan executed on May 3, 2022.
4 Common Common Stock 2023-03-10 M A 15,000 $67.81 502,856 D — — (F1) Trade made pursuant to a 10b5-1 plan executed on May 3, 2022.
5 Derivative Stock Option (Right to buy Common Stock) 2023-03-10 M D 15,000 $0.00 157,130 D $67.81 · 2013-11-15 to 2023-05-14 15,000 Common Stock (F1) Trade made pursuant to a 10b5-1 plan executed on May 3, 2022. (F3) Reflects the number of options outstanding after the transactions from this specific stock option grant.
6 Derivative Stock Option (Right to buy Common Stock) 2023-03-13 M D 8,000 $0.00 149,130 D $67.81 · 2013-11-15 to 2023-05-14 8,000 Common Stock (F2) Trade made pursuant to a 10b5-1 plan executed on November 17, 2022. (F3) Reflects the number of options outstanding after the transactions from this specific stock option grant.